期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 16, 期 3, 页码 421-432出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2016.1136284
关键词
prostate cancer; Cancer immunotherapy; ipilimumab; immune checkpoint; Yervoy
资金
- Bristol-Myers Squibb
Introduction: Ipilimumab is a fully human monoclonal antibody that blocks Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) to potentiate antitumor T cell response. Ipilimumab is approved for the treatment of advanced melanoma based on improved overall survival. Clinical trials of ipilimumab in patients with metastatic castrate-resistant prostate cancer (mCRPC) have demonstrated some clinical activity, but have largely been disappointing to date. Areas covered: Results of key clinical studies of ipilimumab in the treatment of prostate cancer, including clinical efficacy and toxicities, are summarized. Expert opinion: There is likely a clinical benefit to ipilimumab in a subset of mCRPC patients. The development of biomarkers for enrichment treatment strategies that select for patients most likely to benefit from ipilimumab is a top priority. Similarly, an understanding of the factors predictive of toxicity will be important in the development of future treatment approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据